Organon licenses MIUDELLA IUD from Sebela Pharmaceuticals
Gilead to acquire Arcellx to gain full control of anito-cel
Novo Nordisk's CagriSema achieves 23% weight loss but misses primary endpoint in REDEFINE 4 trial
AbbVie's VENCLEXTA (venetoclax) and acalabrutinib combination receives US FDA approval to treat CLL
Vanda Pharmaceuticals' BYSANTI (milsaperidone) tablets receive US FDA approval
FDA approves Genentech oral Venclexta plus AstraZeneca's Calquence combination for first-line CLL
EMA validates Enhertu application for post-neoadjuvant HER2-positive early breast cancer
Merck reports positive Phase 3 data for Enflonsia in high-risk children across two RSV seasons
Hansa's imlifidase Biologics License Application accepted by FDA
Novartis reports positive Phase III results for remibrutinib in chronic inducible urticaria
Cambridge Cognition expands into India through Ivory commercialisation agreement
HanchorBio's HCB101 receives US FDA Orphan Drug Designation in gastric cancer
STADA and Bio-Thera Solutions receive European marketing authorisation for Gotenfia (golimumab)
MEDIPOST files IND amendment to start Phase III trial for knee osteoarthritis therapy